- Home
- NEXN vs ALT Comparison
NEXN vs ALT Comparison
Compare NEXN & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NEXN | ALT |
|---|---|---|
| Founded | 2007 | 1997 |
| Country | Israel | United States |
| Employees | 909 | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 381.1M | 421.5M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | NEXN | ALT |
|---|---|---|
| Price | $7.03 | $3.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $11.56 | ★ $17.67 |
| AVG Volume (30 Days) | 275.7K | ★ 2.6M |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.64 | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $5.60 | $2.87 |
| 52 Week High | $12.00 | $7.73 |
Technical Indicators
Market Signals| Indicator | NEXN | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 59.64 | 42.47 |
| Support Level | $6.23 | $2.87 |
| Resistance Level | $7.71 | $4.25 |
| Average True Range (ATR) | 0.31 | 0.16 |
| MACD | 0.03 | 0.05 |
| Stochastic Oscillator | 81.86 | 60.45 |
Price Performance
Historical ComparisonAbout NEXN Nexxen International Ltd. American Depository Shares
Nexxen International Ltd is a globalized and flexible advertising technology platform with deep expertise in data and TV that helps empower advertisers, agencies, digital publishers, broadcasters, and others. The Digital Advertising Ecosystem of the company includes demand-side platform (DSP), supply-side platform (SSP), ad server, and data management platform (DMP) and also delivers a flexible and unified technology stack with and exclusive data at its core. The company operates in America, APAC, EMEA, and Rest of America, with majority revenue from America.
About ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.